Wells Fargo & Company MN reduced its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 44.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 356,372 shares of the biotechnology company’s stock after selling 287,476 shares during the period. Wells Fargo & Company MN owned 0.54% of Sarepta Therapeutics worth $47,105,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of SRPT. Frontier Capital Management Co. LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $16,940,000. JPMorgan Chase & Co. grew its position in shares of Sarepta Therapeutics by 36.3% in the first quarter. JPMorgan Chase & Co. now owns 709,070 shares of the biotechnology company’s stock valued at $52,535,000 after purchasing an additional 188,841 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $9,209,000. State of New Jersey Common Pension Fund D purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $15,862,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $8,295,000. Institutional investors own 85.00% of the company’s stock.

SRPT opened at $130.25 on Friday. Sarepta Therapeutics Inc has a one year low of $35.26 and a one year high of $176.50. The company has a market capitalization of $8.61 billion, a P/E ratio of -79.42 and a beta of 1.34. The company has a debt-to-equity ratio of 0.62, a quick ratio of 9.89 and a current ratio of 10.88.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.99). Sarepta Therapeutics had a negative net margin of 89.64% and a negative return on equity of 19.34%. The business had revenue of $73.53 million during the quarter, compared to analyst estimates of $71.53 million. During the same quarter in the prior year, the company posted ($0.48) earnings per share. The company’s revenue was up 110.0% on a year-over-year basis. analysts anticipate that Sarepta Therapeutics Inc will post -2.09 EPS for the current year.

In other Sarepta Therapeutics news, SVP Alexander Cumbo sold 33,782 shares of the company’s stock in a transaction on Monday, July 9th. The stock was sold at an average price of $137.32, for a total transaction of $4,638,944.24. Following the transaction, the senior vice president now directly owns 40,690 shares in the company, valued at $5,587,550.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David T. Howton sold 50,000 shares of the company’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $136.46, for a total value of $6,823,000.00. Following the transaction, the senior vice president now owns 37,967 shares in the company, valued at $5,180,976.82. The disclosure for this sale can be found here. Insiders sold 158,782 shares of company stock worth $21,237,444 over the last quarter. 7.90% of the stock is currently owned by insiders.

A number of equities research analysts have recently issued reports on SRPT shares. Needham & Company LLC upped their price target on Sarepta Therapeutics from $75.00 to $109.00 and gave the company a “buy” rating in a research report on Monday, May 7th. Credit Suisse Group set a $92.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Friday, May 4th. Nomura upped their price target on Sarepta Therapeutics to $131.00 and gave the company a “buy” rating in a research report on Friday, May 4th. HC Wainwright set a $96.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Friday, May 4th. Finally, Goldman Sachs Group upped their price target on Sarepta Therapeutics from $84.00 to $127.00 and gave the company a “buy” rating in a research report on Friday, May 18th. Four research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $147.98.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

See Also: Stock Symbols Definition, Examples, Lookup

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.